Skip to main content
$91.50 -$1.35 (-1.5%)

04:30 PM EDT on 08/14/20

Acceleron Pharma (NASDAQ:XLRN)

CAPS Rating: 2 out of 5

Current Price $91.50 Mkt Cap $5.5B
Open $93.17 P/E Ratio 0.00
Prev. Close $92.85 Div. (Yield) $0.00 (0.0%)
Daily Range $91.08 - $93.47 Volume 251,426
52-Wk Range $37.60 - $110.75 Avg. Daily Vol. 916,074

Caps

How do you think NASDAQ:XLRN will perform against the market?

Add Stock to CAPS Watchlist

All Players

37 Outperform
3 Underperform
 

All-Star Players

12 Outperform
0 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:XLRN Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFSpiffyPop (99.87)
Submitted June 29, 2015

Bit of a flyer, but I like orphan-drug companies and in this case the partner is Celgene, a company I greatly esteem. Outperform.

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:XLRN VS S&P 500 (SPY)

Fools bullish on NASDAQ:XLRN are also bullish on:

Fools bearish on NASDAQ:XLRN are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about XLRN.

Recs

0
Member Avatar prezrobert (< 20) Submitted: 4/6/2020 12:18:48 PM : Outperform Start Price: $85.53 NASDAQ:XLRN Score: -20.27

Acceleron Pharma is a biotechnology company focused on the discovery, development, and commercialization of novel therapies. The company's research focuses on key natural regulators of cellular growth and repair. Acceleron generates its revenue through collaboration, licensing, and research arrangements with collaboration partners for the development and commercialization of therapeutic candidates. The company sometimes uses contract research organizations and research institutions outside the United States.

Recs

0
Member Avatar TMFEBCapital (97.31) Submitted: 11/20/2018 11:10:00 AM : Outperform Start Price: $50.39 NASDAQ:XLRN Score: +56.70

Potential for short-term catalyst at ASH in December, longer term catalyst approval of luspatercept for beta thalassemia and MDS. Luspatercept's licensed to the best partner in bone marrow disorders, Celgene, and Celgene owns over 12% of XLRN already. $2 billion peak sales potential for luspatercept suggests XLRN arguably undervalued.

Recs

0
Member Avatar Bigsef77 (69.83) Submitted: 6/29/2018 10:14:54 AM : Outperform Start Price: $28.56 NASDAQ:XLRN Score: +182.90

Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III ‘MEDALIST’ Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes

Leaderboard

Find the members with the highest scoring picks in XLRN.

Score Leader

DoubleBagel

DoubleBagel (35.57) Score: +250.02

The Score Leader is the player with the highest score across all their picks in XLRN.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
K28hill < 20 9/24/2013 Outperform 5Y $20.78 +345.00% +97.79% +247.20 0 Comment
DoubleBagel 35.57 1/23/2017 Outperform 5Y $24.24 +281.48% +49.19% +232.28 0 Comment
stockpickeraz 27.33 9/25/2013 Outperform 3W $22.20 +316.53% +99.07% +217.47 0 Comment
Reallynow222 96.17 2/22/2017 Outperform 5Y $26.41 +250.13% +42.73% +207.40 0 Comment
Hoofer38 52.12 10/23/2013 Outperform 5Y $23.33 +296.36% +93.05% +203.30 0 Comment
Bigsef77 69.83 5/11/2017 5/22/2018 Outperform 3Y $28.56 +223.77% +40.87% +182.90 1 Comment
ReaperKK < 20 9/3/2014 Outperform 3Y $26.58 +247.89% +67.29% +180.61 1 Comment
mdriver78 72.88 7/27/2015 8/3/2020 Outperform 5Y $28.59 +223.43% +62.86% +160.57 1 Comment
TheLusciousLucas 92.18 8/26/2014 Outperform NS $28.53 +224.17% +68.05% +156.12 0 Comment
portefeuille 98.77 5/4/2015 Outperform 5Y $29.57 +212.77% +59.48% +153.28 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for XLRN.